Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Position Decreased by Fourpath Capital Management LLC

Fourpath Capital Management LLC decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,218 shares of the medical equipment provider’s stock after selling 301 shares during the quarter. Intuitive Surgical accounts for about 1.2% of Fourpath Capital Management LLC’s investment portfolio, making the stock its 21st biggest holding. Fourpath Capital Management LLC’s holdings in Intuitive Surgical were worth $6,377,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Berbice Capital Management LLC bought a new stake in Intuitive Surgical in the fourth quarter worth approximately $26,000. Godsey & Gibb Inc. boosted its holdings in Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares in the last quarter. MidAtlantic Capital Management Inc. acquired a new position in Intuitive Surgical during the third quarter worth $33,000. Decker Retirement Planning Inc. bought a new position in Intuitive Surgical during the fourth quarter valued at about $36,000. Finally, Capital Performance Advisors LLP bought a new position in Intuitive Surgical during the third quarter valued at about $38,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

ISRG opened at $578.55 on Tuesday. Intuitive Surgical, Inc. has a fifty-two week low of $364.17 and a fifty-two week high of $616.00. The company has a market capitalization of $206.07 billion, a P/E ratio of 90.26, a P/E/G ratio of 5.51 and a beta of 1.39. The firm’s fifty day moving average price is $550.40 and its two-hundred day moving average price is $510.02.

Insider Activity

In related news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $539.00, for a total transaction of $202,664.00. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,967,734. This trade represents a 6.39 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jamie Samath sold 269 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $539.89, for a total value of $145,230.41. Following the completion of the sale, the insider now owns 8,757 shares in the company, valued at $4,727,816.73. This trade represents a 2.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,843 shares of company stock worth $15,357,560. Corporate insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. CICC Research started coverage on Intuitive Surgical in a report on Monday, January 27th. They set a “neutral” rating and a $550.00 price objective on the stock. Robert W. Baird lifted their price target on shares of Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Wells Fargo & Company upped their price objective on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Morgan Stanley upgraded shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $522.00 to $650.00 in a report on Monday, December 2nd. Finally, Royal Bank of Canada upped their price target on shares of Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.